CELZ Q2 2026: Cash at $8.7M After $4.5M Warrant Exercise, Loss Widens Slightly
CELZ has more than doubled off its 52-week low of $0.62 on elevated volume (6.9× avg).
Summary
CELZ ended Q2 2026 with $8.7M in cash after a $4.5M warrant exercise, extending its runway into 2027. The net loss was flat at $2.9M, but a related-party SPAC investment and massive warrant overhang add risk.
Key Events · Earnings and Guidance · CELZ
-
Cash Runway Extended
Cash rose to $8.7M at June 30, 2026, from $7.2M at year-end, driven by $4.5M in gross proceeds from a June 30 warrant inducement. At the current ~$1.5M quarterly burn, this funds operations into late 2027.
-
Net Loss Flat Year-Over-Year
H1 2026 net loss was $2.9M, nearly unchanged from $2.87M in H1 2025. R&D spending fell 20% to $1.0M as the ADAPT trial moved to follow-up, while SG&A rose 22% to $2.0M on marketing and staffing.
-
Warrant Overhang Grows
Outstanding warrants increased to 8.9M shares (weighted average exercise price $2.22) after the June 2026 inducement issued 5.6M new warrants. A shareholder vote on August 28 seeks to increase authorized shares from 25M to 100M, enabling further exercises.
-
Related-Party SPAC Investment
The company advanced $125,000 to a CEO-controlled entity planning to launch a SPAC. The investment is carried at cost with no impairment, but the lack of a formal agreement and the CEO's dual role raise governance concerns.
Analysis · CELZ · Life Sciences
Creative Medical Technology Holdings reported a net loss of $2.9 million for the first half of 2026, roughly flat year-over-year, but the balance sheet strengthened to $8.7 million in cash after a $4.5 million warrant inducement closed on June 30. The company remains pre-revenue, burning about $1.5 million per quarter, giving it roughly 5–6 quarters of runway at the current pace. The filing also discloses a $125,000 advance to a CEO-controlled SPAC sponsor — a related-party transaction that raises governance questions. With 8.9 million warrants outstanding and a shareholder vote on August 28 to increase authorized shares to 100 million, dilution risk is front and center. The cash position removes near-term survival risk, but the warrant overhang and related-party dealings keep the story mixed.
At the time of this filing, CELZ was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.62 to $6.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.